Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of cariprazine effects on cognition in schizophrenia
2020-005726-29Phase 4Active
- Sponsor
- Medical University of Innsbruck
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cariprazine in schizophrenia, sponsored by Medical University of Innsbruck. Primary endpoints: Change in BACS score from baseline to week 28, Change in HFERST score from baseline to week 28 and 1 more. Started Dec 2020; status: active.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-005726-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005726-29.